Ardelyx Inc
Research Ardelyx Inc (ARDX) on Bullrun: market cap USD 941.78M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerARDX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 941.78M
- Financial periodQ2 2026
- RevenueUSD 120.88M
- Net income-USD 16.72M
- Free cash flow-USD 6.41M
- Gross margin95.2%
Valuation Snapshot
latest market cap is USD 941.78M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 407.32M | -USD 62.00M | -USD 43.98M | 90.3% | -0.26 | USD 68.00M | USD 202.83M | USD 166.95M |
| FY2024 | USD 333.62M | -USD 39.00M | -USD 45.82M | 84.8% | -0.17 | USD 64.93M | USD 150.85M | USD 173.29M |
| FY2023 | USD 124.46M | -USD 66.00M | -USD 90.06M | 85.7% | -0.3 | USD 21.47M | USD 49.82M | USD 166.82M |
| FY2022 | USD 52.16M | -USD 67.00M | -USD 70.10M | 92.1% | -0.42 | USD 96.14M | USD 26.71M | USD 98.33M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 941.78M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.42B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 1.21B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.44B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 534.26M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 143.20M | n/a | n/a | n/a |
About Ardelyx Inc
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Ardelyx Inc's market cap?
Ardelyx Inc's market capitalization is USD 941.78M.
What does Ardelyx Inc do?
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.